This article is for informational and educational purposes only and does not constitute medical advice. Vilon is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Vilon is a synthetic dipeptide with the sequence Lys-Glu (KE) and a molecular weight of approximately 275 Da. It appears to be among the shortest members of the peptide bioregulator class developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, and was developed from research involving thymus-derived peptide fractions. Vilon is proposed to modulate gene expression in immune cells — particularly lymphocytes and thymic epithelial cells — in the context of age-related immune decline. In vitro and animal model studies, conducted predominantly by the originating research group, have examined associations between Vilon and parameters of immune cell activity and lymphocyte function. As with other members of the Khavinson class, the published evidence base for Vilon is limited primarily to studies from the originating laboratory, with research appearing across Russian-language and international journals. No peer-reviewed randomized controlled trial evaluating Vilon in human subjects has been identified as of the review date.
1. Background
1.1 Peptide Bioregulators — The Khavinson Framework
The peptide bioregulator concept was developed in the Soviet Union and subsequently Russia beginning in the 1970s by Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg. The foundational hypothesis proposes that short peptides — typically 2–4 amino acids derived from or modeled on organ-specific tissue extracts — can regulate gene expression in a tissue-targeted manner, with proposed applications in aging biology and age-related disease. The proposed mechanism involves direct interaction of these short peptides with DNA regulatory elements such as gene promoter sequences, influencing transcription of genes relevant to the targeted tissue type [3].
Vilon represents the immune-targeted arm of this program, alongside related compounds addressing other tissue systems: Epitalon (Ala-Glu-Asp-Gly) for the pineal gland, Cartalax (Ala-Glu-Asp) for cartilage, and Vesugen (Lys-Glu-Asp) for vascular endothelium. As a dipeptide, Vilon is the minimum-length representative of the class — two amino acids rather than the three or four residues that characterize most other members. The biological basis for tissue-specificity across the class has not been independently established [1].
1.2 Thymic Biology and Age-Related Immune Decline
The thymus is the primary lymphoid organ responsible for T-lymphocyte maturation. Precursor T-cells (thymocytes) migrate from bone marrow to the thymus, where they undergo selection processes that generate a functional, self-tolerant T-cell repertoire. Naïve T-cells exiting the thymus seed the peripheral immune system, maintaining immune surveillance and adaptive immune responses throughout life [4].
Thymic involution — the progressive replacement of productive lymphoid tissue with adipose tissue — begins in early adulthood and accelerates with aging. By the sixth and seventh decades of life, the majority of thymic parenchyma has been replaced by fat, and the output of naïve T-cells from the thymus declines substantially. This decline in thymopoiesis contributes to immunosenescence: a broad age-associated remodelling of the immune system characterised by contraction of the naïve T-cell pool, accumulation of terminally differentiated effector-memory T-cells, reduced responsiveness to new antigens, and impaired vaccine responses [5]. The thymus has consequently been a target of interest for strategies aimed at supporting immune function in aging.
1.3 Development of Vilon and Relationship to Thymalin
The Khavinson group developed both Thymalin — a polypeptide extract derived from bovine thymus tissue — and Vilon, which represents an attempt to identify and synthesize a minimal bioactive peptide sequence from thymic fractions. The KE dipeptide was identified through the group’s fractionation and bioassay program as a candidate thymic bioregulator, and Vilon was subsequently synthesized and studied as a defined, single-sequence compound. As a synthetic dipeptide, Vilon provides a more chemically defined research tool than whole thymic extracts, though the mechanistic relationship between the KE sequence and endogenous thymic peptide biology has not been independently characterized.
2. Molecular Structure
Vilon is a dipeptide with the sequence Lys-Glu, abbreviated in single-letter code as KE. At two residues and approximately 275 Da, it is the smallest peptide in the Khavinson bioregulator class. The lysine side chain carries a positive charge and the glutamic acid side chain a negative charge at physiological pH, and these are offset by the terminal groups, giving Vilon a net charge of approximately zero at pH 7.4.
| Property | Detail |
|---|---|
| Sequence | Lys-Glu (KE) |
| Peptide length | 2 amino acids (dipeptide) |
| Molecular weight | ~275 Da |
| Net charge (pH 7.4) | ~0 (Lys side chain +1 offset by Glu side chain −1; terminal groups balance) |
| Related bioregulators | Vesugen (Lys-Glu-Asp, KED); Thymalin (thymic polypeptide complex) |
| Structural note | KE is identical to the N-terminal dipeptide of Vesugen (KED) |
| Proposed tissue target | Thymus / immune lymphocytes |
| Developer | Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology |
3. Proposed Mechanisms
The proposed mechanisms of Vilon follow the general bioregulator framework applied by the Khavinson group across the peptide class. Each proposed mechanism below remains incompletely characterized and has not been independently validated. The label “Proposed” in each card reflects this status.
4. Key Research Findings
4.1 In Vitro Lymphocyte and Immune Cell Studies
Cell-based studies from the Khavinson group have examined Vilon in lymphocyte culture models, reporting associations with parameters of lymphocyte proliferation, cell viability under stress conditions, and markers related to immune cell activation and gene expression. These studies follow the methodology common to the broader bioregulator research program: exposure of cultured immune cells to the KE dipeptide, followed by assessment of target gene or protein expression. Reported associations were interpreted by the originating group as directionally consistent with the proposed immune-supportive rationale for the compound, though effect magnitude, concentration dependence, and specificity relative to other short peptides have not been characterized in published independent studies.
The pharmacokinetic relevance of in vitro studies is particularly uncertain for Vilon given its dipeptide structure. The concentrations used in cell culture systems may substantially exceed what could be achieved in peripheral blood or lymphoid tissue following subcutaneous administration, given the rapid degradation expected for a freely circulating dipeptide.
4.2 Animal Model Studies
Animal studies examining Vilon effects on immune parameters have been conducted within the Khavinson group’s research program, employing rodent models and assessing markers of immune cell populations, lymphocyte function, and histological features of thymic and lymphoid tissue. Published studies from the originating group report associations interpreted by the originating group as consistent with immune-supportive effects in aging animal models, though the methodological details, dosing protocols, and reproducibility of these findings across independent studies remain incompletely characterized in accessible literature.
4.3 Relationship to Thymalin and Class Context
Vilon was developed in parallel with Thymalin, a polypeptide extract from bovine thymus that was studied more extensively by the Khavinson group in the context of aging and immune function. Anisimov and Khavinson (2010) reviewed the evidence base for both thymic-targeted compounds alongside other members of the bioregulator class, situating Vilon as the synthetic dipeptide counterpart to Thymalin’s complex polypeptide mixture [2]. The overlap between Thymalin and Vilon evidence bases means care is needed when interpreting studies that discuss both compounds: the findings attributed to Thymalin cannot be assumed to apply to the defined KE dipeptide, and vice versa.
Qualitative representation of the relative volume and stage of available evidence for Vilon. Bar lengths are schematic and do not represent quantitative study counts. All available research originates from the Khavinson group; independent replication has not been published as of the review date.
5. Evidence Status
| Proposed Effect / Claim | Current Status | Evidence Level |
|---|---|---|
| Gene promoter interaction (in silico) | Computational modeling from originating group; no independent experimental validation published | Limited |
| Lymphocyte activity modulation (in vitro) | Cell-based studies from originating group; not independently replicated in published literature | Limited |
| Immune parameters in animal models | Animal studies from originating group; limited accessible detail; not independently replicated | Limited |
| Thymic epithelial cell support | Proposed from class-level framework; Vilon-specific independent data not published | Limited |
| Cytokine / immune mediator modulation | Proposed from class-level framework; not independently characterized for Vilon specifically | Limited |
| Efficacy or safety in humans (any indication) | No peer-reviewed randomized controlled trial identified as of the review date | Limited |
What We Still Don’t Know
- Dipeptide plasma stability and transport: Dipeptides are subject to extremely rapid degradation by plasma peptidases, including dipeptidyl peptidase IV and non-specific aminopeptidases. Whether the KE dipeptide survives intact in plasma for a duration sufficient to reach immune tissue at biologically meaningful concentrations has not been established in published pharmacokinetic studies. Dipeptide transporters (PEPT1, PEPT2) can facilitate intact uptake of dipeptides in intestinal and renal epithelial cells, but whether this mechanism applies to Vilon in immune tissue is uncharacterized.
- Mechanism of immune tissue selectivity: The basis by which Vilon would preferentially influence gene expression in thymic or peripheral immune cells rather than other tissues encountered systemically has not been independently explained or demonstrated. This is an unresolved fundamental question across the Khavinson bioregulator class and is arguably more acute for a dipeptide than for longer peptides.
- Distinguishing Vilon effects from Thymalin: Published research from the originating group has studied both Vilon (KE dipeptide) and Thymalin (thymus polypeptide complex) in related contexts. Whether the effects attributed to Thymalin in older studies are attributable specifically to the KE sequence, other peptide components, or the complex mixture as a whole has not been established through comparative independent research.
- Long-term safety: No published preclinical toxicology data or human safety information are available for Vilon as a defined compound. The effects of chronic dipeptide exposure on immune cell biology or off-target tissues are unknown from published evidence.
- Independent replication of any finding: No study from a research group independent of the Khavinson laboratory has published findings specific to Vilon in peer-reviewed form as of the review date, making reproducibility assessment impossible from available literature.
6. Limitations of Current Research
References
- Khavinson VKh, Morozov VG. “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters. 2003;24(3–4):233–240.
- Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139–149. doi:10.1007/s10522-009-9249-8
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. “Mechanism of short peptides interaction with DNA.” Advances in Gerontology. 2014;27(4):706–714.
- Gruver AL, Hudson LL, Sempowski GD. “Immunosenescence of ageing.” Journal of Pathology. 2007;211(2):144–156. doi:10.1002/path.2104
- Dixit VD. “Thymic fatness and approaches to enhance thymopoietic fitness in aging.” Current Opinion in Immunology. 2010;22(4):521–528. doi:10.1016/j.coi.2010.06.010